What is the role of thymidine phosphorylase inhibitor in TAS-102, a novel nucleoside antitumor agent?
['["PURPOSE: Trifluridine (TFT) is an antitumor component of a novel nucleoside antitumor agent, TAS-102, which consists of TFT and tipiracil hydrochloride (thymidine phosphorylase inhibitor).", "TAS-102, a combination of trifluorothymidine and the thymidine phosphorylase inhibitor TPI in a 1:0.5 ratio, is a novel oral formulation, which is active in 5FU-resistant models, both in vitro and in xenograft models.", "TAS-102 is a novel oral nucleoside antitumor agent consisting of trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. ", "PURPOSE: TAS-102 is an orally administered anticancer agent composed of \\u03b1,\\u03b1,\\u03b1-trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). ", "Novel DNA synthesis inhibitors for the treatment of gastrointestinal malignancies include a combination of the antimetabolite TAS-102, which consists of trifluorothymidine with a thymidine phosphorylase inhibitor, and a novel micellar formulation of cisplatin NC-6004 that uses a nanotechnology-based drug delivery system. ", "Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.", "TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine (FTD) and tipiracil hydrochloride (TPI)."]']
The thymidine phosphorylase inhibitor in TAS-102, a novel nucleoside antitumor agent, is designed to inhibit the enzyme thymidine phosphorylase, which helps increase the concentration of trifluridine in the tumor cells by preventing its breakdown. This leads to enhanced antitumor activity.
[]